SpringWorks, Merck Group

UPDATE: Merck KGaA sets its sights on acquisition of Ogsiveo maker SpringWorks
As SpringWorks Therapeutics nears a key regulatory decision in the U.S., the Connecticut-based cancer and rare disease drugmaker has attracted the attention of a biopharma bigwig from overseas. | Merck KGaA is in advanced talks to acquire cancer and rare disease specialist SpringWorks,
Merck KGaA in Talks to Buy SpringWorks Therapeutics
Merck KGaA said it’s in advanced talks to purchase SpringWorks Therapeutics Inc., sending shares of the US cancer and rare diseases drugmaker soaring.
Germany's Merck in advanced talks to acquire US biotech firm SpringWorks
(Corrects third to last paragraph to say "the erosion from LOEs (loss of exclusivity)", not "from LOEs (levels of evidence)") By Sabrina Valle and Patricia Weiss NEW YORK/FRANKFURT (Reuters) -Merck KGaA,
Merck In Talks to Buy Cancer Drugmaker Springworks
After a slow 2024, dealmaking in the U.S. healthcare sector is picking up. Springworks has a market value of $3 billion.
EQS-Adhoc: Merck KGaA: Merck KGaA confirms discussions with Springworks Therapeutics, Inc. on potential acquisition
Merck KGaA (“Merck”) reacts to press reports and confirms advanced discussions with Springworks Therapeutics, Inc. Merck also confirms that no legally binding agreement has been entered into. There is no certainty that any transaction will materialize.
Merck KGaA in advanced talks to acquire SpringWorks Therapeutics
KGaA said it is in advanced discussions regarding a potential acquisition of SpringWorks Therapeutics, a U.S. biopharmaceutical firm specializing in rare diseases and cancer treatments.
STAT10d
Merck’s earnings miss focused attention on Gardasil. The real issue is Keytruda
Merck on Tuesday missed earnings estimates, lowered its guidance for this year’s earnings, and withdrew a target for sales of ...
Merck touts 20 new ‘blockbuster’ drugs in development with $50 billion potential
Merck's latest earnings call revealed a mix of growth and pain points for the pharmaceutical giant.
China leaves Merck in need of a new profit injection
Chinese consumers, once the engine of growth for multinational companies, are cutting back on all kinds of things. Designer ...
The drug industry is having its own DeepSeek moment
It isn’t just artificial intelligence. Chinese biotech companies are now developing drugs faster and cheaper than their US ...
BioPharma Dive3d
Merck KGaA pursuing Springworks; BridgeBio wins EU drug OK
The German drugmaker confirmed acquisition talks, but cautioned a deal may not materialize. Elsewhere, Biohaven got priority ...
GlobalData on MSN2d
FDA approves Gomekli as first neurofibromatosis drug for adults
The US Food and Drug Administration (FDA) has approved SpringWorks Therapeutics’ Gomekli (mirdametinib) to treat ...
Why Merck Stock Is Plummeting Today
Merck's stock sank after the company reported fourth-quarter and year-end 2024 earnings this morning. Although it narrowly ...
BioSpace2d
SpringWorks Wins FDA Nod for Neurofibromatosis Drug, Tees Up Challenge to AstraZeneca
The FDA on Tuesday signed off on SpringWorks Therapeutics’ mirdametinib—now to carry the brand name Gomekli—for the treatment ...